JP5183854B2 - 二量体化合物および抗ウイルス薬としてのそれらの使用 - Google Patents

二量体化合物および抗ウイルス薬としてのそれらの使用 Download PDF

Info

Publication number
JP5183854B2
JP5183854B2 JP2003542182A JP2003542182A JP5183854B2 JP 5183854 B2 JP5183854 B2 JP 5183854B2 JP 2003542182 A JP2003542182 A JP 2003542182A JP 2003542182 A JP2003542182 A JP 2003542182A JP 5183854 B2 JP5183854 B2 JP 5183854B2
Authority
JP
Japan
Prior art keywords
compound
amino
phenyl
formula
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003542182A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005511609A (ja
Inventor
デレック、エー．デマイン
ハイドン、ティー．ジョーンズ
サイモン、ジェイ．エフ．マクドナルド
アンドリュー、マックエム．メイソン
スティーブン、イー．シャナハン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biota Scientific Management Pty Ltd
Original Assignee
Biota Scientific Management Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biota Scientific Management Pty Ltd filed Critical Biota Scientific Management Pty Ltd
Publication of JP2005511609A publication Critical patent/JP2005511609A/ja
Application granted granted Critical
Publication of JP5183854B2 publication Critical patent/JP5183854B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2003542182A 2001-11-09 2002-11-08 二量体化合物および抗ウイルス薬としてのそれらの使用 Expired - Fee Related JP5183854B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPR8797A AUPR879701A0 (en) 2001-11-09 2001-11-09 Novel chemical compounds and their use
AUPR8797 2001-11-09
PCT/AU2002/001526 WO2003040136A1 (en) 2001-11-09 2002-11-08 Dimeric compounds and their use as anti-viral agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010161515A Division JP2010285436A (ja) 2001-11-09 2010-07-16 二量体化合物および抗ウイルス薬としてのそれらの使用

Publications (2)

Publication Number Publication Date
JP2005511609A JP2005511609A (ja) 2005-04-28
JP5183854B2 true JP5183854B2 (ja) 2013-04-17

Family

ID=3832616

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003542182A Expired - Fee Related JP5183854B2 (ja) 2001-11-09 2002-11-08 二量体化合物および抗ウイルス薬としてのそれらの使用
JP2010161515A Withdrawn JP2010285436A (ja) 2001-11-09 2010-07-16 二量体化合物および抗ウイルス薬としてのそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010161515A Withdrawn JP2010285436A (ja) 2001-11-09 2010-07-16 二量体化合物および抗ウイルス薬としてのそれらの使用

Country Status (9)

Country Link
US (2) US7214707B2 (enExample)
EP (1) EP1451183A4 (enExample)
JP (2) JP5183854B2 (enExample)
KR (1) KR100942494B1 (enExample)
CN (1) CN100345842C (enExample)
AU (2) AUPR879701A0 (enExample)
CA (1) CA2463835C (enExample)
TW (1) TW200303196A (enExample)
WO (1) WO2003040136A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR879701A0 (en) 2001-11-09 2001-12-06 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
CN108047153A (zh) * 2017-12-20 2018-05-18 上海朗亿功能材料有限公司 一种低挥发环状碳化二亚胺类化合物及其制备方法
KR20210079278A (ko) * 2018-09-06 2021-06-29 시다라 세라퓨틱스, 인코포레이티드 바이러스 감염의 치료를 위한 조성물 및 방법
TWI861205B (zh) * 2019-09-06 2024-11-11 美商席達拉醫療有限公司 用於治療病毒感染之組合物及方法
CN110981753A (zh) * 2019-12-19 2020-04-10 山东华阳农药化工集团有限公司 一种碳酸二甲酯法制备二苯基乙烷二异氰酸酯及其应用
CN110903216A (zh) * 2019-12-19 2020-03-24 山东华阳农药化工集团有限公司 一种固体光气法制备二苯基乙烷二异氰酸酯及其应用
CN110981754A (zh) * 2019-12-19 2020-04-10 山东华阳农药化工集团有限公司 一种二苯基乙烷二异氰酸酯及其制备方法
CN116367866A (zh) * 2020-08-06 2023-06-30 奇达拉治疗公司 蛋白质-药物偶联物的合成方法
US20230364251A1 (en) * 2020-08-06 2023-11-16 Cidara Therapeutics, Inc. Methods for the synthesis of protein-drug conjugates
WO2022192685A1 (en) * 2021-03-11 2022-09-15 Cidara Therapeutics, Inc. Protein-drug conjugates for antiviral therapy
CN118678970A (zh) * 2021-12-30 2024-09-20 苏州爱科百发生物医药技术有限公司 用于预防和治疗病毒感染的偶联物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3409295A (en) * 1994-08-18 1996-03-14 Ariad Gene Therapeutics, Inc. Regulatable elimination of gene expression, gene product function and engineered host cells
GB9516276D0 (en) * 1995-08-08 1995-10-11 Biota Scient Management Chemical compounds
IL125662A0 (en) * 1996-03-01 1999-04-11 Biota Scient Management Method of detecting influenza virus and compounds for use therein
AUPP913999A0 (en) * 1999-03-12 1999-04-01 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
AUPR001000A0 (en) 2000-09-08 2000-10-05 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
AUPR879701A0 (en) 2001-11-09 2001-12-06 Biota Scientific Management Pty Ltd Novel chemical compounds and their use

Also Published As

Publication number Publication date
KR20050044339A (ko) 2005-05-12
WO2003040136A1 (en) 2003-05-15
KR100942494B1 (ko) 2010-02-12
JP2005511609A (ja) 2005-04-28
CA2463835A1 (en) 2003-05-15
US20050054718A1 (en) 2005-03-10
AUPR879701A0 (en) 2001-12-06
US20070225361A1 (en) 2007-09-27
US7214707B2 (en) 2007-05-08
EP1451183A4 (en) 2006-03-15
CN100345842C (zh) 2007-10-31
US7504434B2 (en) 2009-03-17
TW200303196A (en) 2003-09-01
CN1585764A (zh) 2005-02-23
JP2010285436A (ja) 2010-12-24
AU2002340634B2 (en) 2008-03-20
EP1451183A1 (en) 2004-09-01
CA2463835C (en) 2011-09-27

Similar Documents

Publication Publication Date Title
JP2010285436A (ja) 二量体化合物および抗ウイルス薬としてのそれらの使用
JP5095066B2 (ja) 多価ノイラミニダーゼ阻害物質複合体
US6548476B1 (en) Dimeric inhibitors of influenza neuraminidase
JP2010270130A (ja) 二量体化合物および抗ウイルス薬としてのそれらの使用
JP5179546B2 (ja) 二量体化合物および抗ウイルス薬としてのそれらの使用
AU2002340634A1 (en) Dimeric compounds and their use as anti-viral agents
JP2011016804A (ja) 二量体化合物および抗ウイルス薬としてのそれらの使用

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051013

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20090527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090529

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090831

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090907

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090929

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091029

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130116

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160125

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees